Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 2 (1)
P 3 (1)

Trial Status

Unknown1
Recruiting1
Not Yet Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT06649474Not ApplicableRecruiting

Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1

NCT06057220Not Yet RecruitingPrimary

IMaC - Immune Pathways in Oesophagogastric Cancer

NCT00450203Phase 2UnknownPrimary

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

NCT00824785Phase 3TerminatedPrimary

REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer

Showing all 4 trials

Research Network

Activity Timeline